Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367945 | 0.87 | ALDH1A1 (0.44) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL2040632 | 0.81 | PARP1 (0.53) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL827965 | 0.79 | MAPT (0.55) | MAPTKMT2ASMN1; SMN2POLBHTT | |
| SCHEMBL1198049 | 0.76 | ADORA2A (0.50) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL10927218 | 0.74 | ADORA2A (0.60) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL9241413 | 0.73 | ADORA2A (0.55) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL10546429 | 0.73 | ADORA2A (0.58) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL20334889 | 0.73 | MAPT (0.60) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL1764840 | 0.71 | ADORA2A (0.66) | MAPTKMT2ASMN1; SMN2HKDC1POLB | |
| SCHEMBL30420926 | 0.71 | ALDH1A1 (0.61) | MAPTKMT2APOLBHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101928243-B | Acenaphtho heterocyclic compounds, and cyclodextrin inclusion compounds or conjugates thereof and application thereof in preparing Bcl-2 family protein inhibitors | UNIV DALIAN TECH | 2012-09-05 | — | — | CN | disclosed |
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2011-10-13 | — | — | US | disclosed |
| EP-2366701-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | Dalian University Of Technology (CN) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | BID, BCL2, BAX | MAPT 2488/4885KMT2A 4394/4885SMN1; SMN2 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.